A multicenter study of central nervous system (CNS) metastasis in EGFR-mutated advanced non–small-cell lung cancer in Thailand: CNS progression-free survival analysis. This is an ASCO Meeting Abstract ...

Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix Part 2 of the ...

Please provide your email address to receive an email when new articles are posted on . Most patients treated with BRAF and MEK inhibitors for histiocytic disorders showed no active disease.

“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma BRAF ...

BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...

A new research paper titled "Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells" has been published in Oncotarget. Drug resistance is a major ...

HOUSTON ― Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center ...

In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population. Non-V600 mutations ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today reported updated safety and efficacy data from the Phase 1/2a clinical trial evaluating plixorafenib (FORE8394; PLX8394), a novel, ...

Please provide your email address to receive an email when new articles are posted on . The triplet combination of vemurafenib/cobimetinib/atezolizumab showed ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics today announced new nonclinical data related to plixorafenib (FORE8394; formerly PLX8394), the company's novel, investigational, small-molecule, ...